[Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase].
Primary limb melanoma may recur in terms of satellitosis, in transit metastases and/or regional node involvement. Hyperthermic antiblastic perfusion (HAP) permits the isolation of involved extremity from the systemic circulation and to deliver high doses of antineoplastic drugs. The association of cytostatic drugs to hyperthermia (> or = 41.5 degrees C) results in a synergistic effect with an increased therapeutic effectiveness. The overall 5 and 10-year survival rates in relation to the disease stages are st. II 75% and 67%; st. IIIA 59% and 42%; st. IIIAB 36% and 30% respectively. The results confirm that HAP is considered the treatment of choice of loco-regional spreading limb melanoma. Recently, the tumor necrosis factor (TNF) has been combined with Melphalan and hyperthermia. This trimodality association seems to be superior to Melphalan and hyperthermia alone only in patient with bulky tumors (i.e., multiple nodules), as a matter of fact the complete tumor response rates observed in these patients have been 67% and 20% respectively. The greater effectiveness of trimodality association has to be confirmed by multicentric randomized trials.
Di Filippo
F
F
Polo Oncologico, Istituto Regina Elena, Roma.
Garinei
R
R
Anzà
M
M
Cavaliere
F
F
Botti
C
C
Perri
P
P
Di Filippo
S
S
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D005121:Extremities; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use*; D009361:Neoplasm Invasiveness; D012878:Skin Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use
D018906:Antineoplastic Agents, Alkylating; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan